Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

241. Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based Study From the Netherlands

Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based Study From the Netherlands 26314526 2015 08 28 2015 11 16 2016 08 10 1558-3597 66 9 2015 Sep 01 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based Study From the Netherlands. 1000-7 10.1016/j.jacc.2015.06.1314 S0735-1097(15)04269 (...) -2 Important improvements have been made in treatment of diseases associated with atrial fibrillation (AF), such as hypertension, myocardial infarction, and heart failure. Incidence rates and risk factors may have changed with the aging of the population and changing lifestyles. Currently, the risk for AF is only partially explained, possibly because of differences between older cohorts and contemporary populations. This study investigated the incidence of AF in a contemporary cohort

EvidenceUpdates2015

242. Catheter ablation for treatment of atrial fibrillation

Catheter ablation for treatment of atrial fibrillation Catheter ablation for treatment of atrial fibrillation Catheter ablation for treatment of atrial fibrillation Skelly A, Hashimoto R, Al-Khatib S, Sanders-Schmidler G, Fu R, Brodt E, McDonagh M Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Skelly A, Hashimoto R, Al-Khatib S, Sanders-Schmidler G, Fu R, Brodt (...) E, McDonagh M. Catheter ablation for treatment of atrial fibrillation. Rockville: Agency for Healthcare Research and Quality (AHRQ). Technology Assessment Report. 2015 Authors' objectives This report evaluates the current state of evidence regarding effectiveness and harms of catheter ablation for atrial fibrillation (AF) with a focus on longer-term outcomes and evidence relevant to the Medicare population. Authors' conclusions There was insufficient evidence to draw conclusions regarding

Health Technology Assessment (HTA) Database.2015

244. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan

Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan 26383720 2015 09 19 2016 01 15 2015 09 19 1558-3597 66 12 2015 Sep 22 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. 1339-47 10.1016/j.jacc.2015.07.026 S0735-1097(15)04516-7 Recent studies from Asia have suggested that the risk of ischemic (...) stroke for patients with atrial fibrillation (AF) with a "low-risk" congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65 to 74, female (CHA2DS2-VASc) score of 0 (for males) or 1 (for females) might be higher than that for non-Asians. This study hypothesized that the age threshold (65 years) used in the CHA2DS2-VASc system for initiating oral anticoagulants (OACs) might be lower in Taiwanese AF patients than in non

EvidenceUpdates2015

246. Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients

Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients | CADTH.ca Find the information you need Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients Published on: September 14, 2015 Project Number: OP0523 Product Line: Result (...) type: Report CADTH undertook a health technology assessment (HTA) to inform decision-making about the appropriate use of monitoring for atrial fibrillation (AF) in discharged stroke and transient ischemic attack (TIA) patients. The HTA addressed the clinical and cost-effectiveness of AF ambulatory monitoring devices in outpatient stroke and TIA patients, and identified patient perspectives regarding the value and impact of the AF monitoring devices on their health, health care, and quality

CADTH - Optimal Use2015

247. Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients

Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients | CADTH.ca Find the information you need Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients Published on: September 14, 2015 Project Number: OP0523 Product Line: Result (...) type: Report CADTH undertook a health technology assessment (HTA) to inform decision-making about the appropriate use of monitoring for atrial fibrillation (AF) in discharged stroke and transient ischemic attack (TIA) patients. The HTA addressed the clinical and cost-effectiveness of AF ambulatory monitoring devices in outpatient stroke and TIA patients, and identified patient perspectives regarding the value and impact of the AF monitoring devices on their health, health care, and quality

CADTH - Optimal Use2015

249. Report in Brief - Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation

Report in Brief - Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation Warfarin Management for Thromboembolic Events in Atrial Fibrillation | CADTH.ca Find the information you need Warfarin Management for Thromboembolic Events in Atrial Fibrillation Warfarin Management for Thromboembolic Events in Atrial Fibrillation Published on: August 15, 2011 Project Number: OP0508 Product Line: Result type: Report Warfarin has been the mainstay of oral (...) anticoagulant therapy for more than 60 years. The effectiveness of warfarin for the prevention of stroke in patients with atrial fibrillation is well established. In Canada, an estimated 200,000 to 250,000 people have this condition. Need for Recommendations Managing warfarin therapy is challenging because warfarin interacts with many foods and other drugs. Each patient needs an individualized warfarin dose, which takes time to determine and requires patients to go in for frequent laboratory testing

CADTH - Optimal Use2015

250. Clinical efficacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial fibrillation

Clinical efficacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial fibrillation 26254755 2015 12 24 2016 04 25 2015 12 24 1097-685X 151 1 2016 Jan The Journal of thoracic and cardiovascular surgery J. Thorac. Cardiovasc. Surg. Clinical efficacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial fibrillation. 80-5 10.1016/j.jtcvs.2015.06.061 S0022-5223(15)01089-2 Postoperative atrial fibrillation is the most frequent (...) complication arising after cardiac surgery, occurring in 40% of cases. The treatment of postoperative atrial fibrillation with epicardial amiodarone/corticosteroid hydrogel delivery can increase efficacy and reduce side effects. To further evaluate whether amiodarone hydrogel is superior to corticosteroid hydrogel or placebo, we performed a randomized prospective study in 150 patients with coronary artery bypass grafting to compare the effectiveness with different epicardial drug approaches

EvidenceUpdates2015

251. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.

Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. IMPORTANCE: The CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75 years, sex category [female]) is used clinically for stroke (...) risk stratification in atrial fibrillation (AF). Its usefulness in a population of patients with heart failure (HF) is unclear. OBJECTIVE: To investigate whether CHA2DS2-VASc predicts ischemic stroke, thromboembolism, and death in a cohort of patients with HF with and without AF. DESIGN, SETTING, AND POPULATION: Nationwide prospective cohort study using Danish registries, including 42 987 patients (21.9% with concomitant AF) not receiving anticoagulation who were diagnosed as having incident HF

JAMA2015

252. Catheter Ablation for Persistent Atrial Fibrillation.

Catheter Ablation for Persistent Atrial Fibrillation. Catheter Ablation for Persistent Atrial Fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26308689 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Aug 27;373(9):878-9. doi: 10.1056/NEJMc1508689. Catheter Ablation for Persistent Atrial Fibrillation. , , . Comment on [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] PMID: 26308689 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Full Text Sources Medical PubMed

NEJM2015

253. Catheter Ablation for Persistent Atrial Fibrillation.

Catheter Ablation for Persistent Atrial Fibrillation. Catheter Ablation for Persistent Atrial Fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26308690 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Aug 27;373(9):877. doi: 10.1056/NEJMc1508689#SA1. Catheter Ablation for Persistent Atrial Fibrillation. , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26308690 DOI: [Indexed for MEDLINE] Publication types MeSH terms Full Text Sources Medical PubMed Commons 0 comments How to cite this comment

NEJM2015 Full Text: Link to full Text with Trip Pro

254. Catheter Ablation for Persistent Atrial Fibrillation.

Catheter Ablation for Persistent Atrial Fibrillation. Catheter Ablation for Persistent Atrial Fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26308691 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Aug 27;373(9):877-8. doi: 10.1056/NEJMc1508689#SA2. Catheter Ablation for Persistent Atrial Fibrillation. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26308691 DOI: [Indexed for MEDLINE] Publication types MeSH terms Full Text Sources Medical PubMed Commons 0 comments How to cite this comment

NEJM2015 Full Text: Link to full Text with Trip Pro

255. Catheter Ablation for Persistent Atrial Fibrillation.

Catheter Ablation for Persistent Atrial Fibrillation. Catheter Ablation for Persistent Atrial Fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26308692 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Aug 27;373(9):878. doi: 10.1056/NEJMc1508689#SA3. Catheter Ablation for Persistent Atrial Fibrillation. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26308692 DOI: [Indexed for MEDLINE] Publication types MeSH terms Full Text Sources Medical PubMed Commons 0 comments How to cite this comment

NEJM2015 Full Text: Link to full Text with Trip Pro

256. Warfarin Management for Thromboembolic Events in Atrial Fibrillation

Warfarin Management for Thromboembolic Events in Atrial Fibrillation Warfarin Management for Thromboembolic Events in Atrial Fibrillation | CADTH.ca Find the information you need Warfarin Management for Thromboembolic Events in Atrial Fibrillation Warfarin Management for Thromboembolic Events in Atrial Fibrillation Published on: August 15, 2011 Project Number: OP0508 Product Line: Result type: Report Warfarin has been the mainstay of oral anticoagulant therapy for more than 60 years (...) . The effectiveness of warfarin for the prevention of stroke in patients with atrial fibrillation is well established. In Canada, an estimated 200,000 to 250,000 people have this condition. Need for Recommendations Managing warfarin therapy is challenging because warfarin interacts with many foods and other drugs. Each patient needs an individualized warfarin dose, which takes time to determine and requires patients to go in for frequent laboratory testing of their blood to monitor

CADTH - Optimal Use2015

257. Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence

Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence | CADTH.ca Find the information you need Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical (...) Evidence Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence Published on: August 20, 2012 Product Line: , CADTH Technology Overviews Issue: Volume 2, Issue 3 Result type: Report Adapted from . [Optimal Use Report; Volume 1, Issue 2A]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. For more information on this project, visit Introduction Atrial fibrillation (AF) is the most common

CADTH - Health Technology Assessment2015

258. Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation

Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation | CADTH.ca Find the information you need Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Published on: June (...) 28, 2013 Product Line: , CADTH Technology Overviews Issue: Volume 3, Issue 2 Result type: Report Adapted from Canadian Agency for Drugs and Technologies in Health. (Therapeutic Review) . Ottawa: Canadian Agency for Drugs and Technologies in Health; 2013. For more information on this project, visit Introduction Atrial fibrillation (AF) is a common cardiac arrhythmia associated with increased morbidity and mortality. 1,2 Patients with AF are at increased risk of stroke and systemic embolism (SSE

CADTH - Health Technology Assessment2015

259. Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence

Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence | CADTH.ca Find the information you need Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical (...) Evidence Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence Published on: August 20, 2012 Product Line: , CADTH Technology Overviews Issue: Volume 2, Issue 3 Result type: Report Adapted from . [Optimal Use Report; Volume 1, Issue 2A]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. For more information on this project, visit Introduction Atrial fibrillation (AF) is the most common

CADTH - Health Technology Assessment2015

260. Antithrombotic Therapy for Patients with Atrial Fibrillation

Antithrombotic Therapy for Patients with Atrial Fibrillation Antithrombotic Therapy for Patients with Atrial Fibrillation | CADTH.ca Find the information you need Antithrombotic Therapy for Patients with Atrial Fibrillation Antithrombotic Therapy for Patients with Atrial Fibrillation Published on: June 28, 2012 Project Number: TR0003 Product Line: Therapeutic Review Result type: Report CADTH previously reviewed the and the for patients with atrial fibrillation. The Antithrombotic Therapy (...) for Patients With Atrial Fibrillation project was an extension of the previous review of new oral anticoagulants, and it assessed all antithrombotic drugs currently used to prevent stroke in patients with atrial fibrillation: antiplatelet drugs such as acetylsalicylic acid (ASA) and clopidogrel anticoagulant drugs such as warfarin, dabigatran, rivaroxaban, and apixaban. Tools The Canadian Agency for Drugs and Technologies in Health (CADTH) developed the following tools to help transition our

CADTH - Therapeutic Review2015